Anavex Life Sciences Corp. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AVXL Nasdaq 2836 www.anavex.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Anavex Life Sciences Corp.

Anavex Life Sciences Touts Oral Alzheimer’s Drug Blarcamesine Data, Cash Runway at Healthcare Conference - Mar 5th, 2026 6:27 am
Anavex Life Sciences to Present at the Citizens Life Sciences Conference - Mar 3rd, 2026 5:30 am
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference - Feb 25th, 2026 5:30 am
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors - Feb 23rd, 2026 5:30 am
3 Promising Penny Stocks With At Least $200M Market Cap - Feb 13th, 2026 5:05 am
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know - Feb 12th, 2026 10:00 am
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? - Feb 12th, 2026 7:40 am
High Growth Tech Stocks In US With Promising Potential - Feb 10th, 2026 4:38 am
Breakeven On The Horizon For Anavex Life Sciences Corp. (NASDAQ:AVXL) - Feb 10th, 2026 3:44 am
Anavex Life Sciences Q1 Earnings Call Highlights - Feb 9th, 2026 8:06 am
Anavex (AVXL) Q1 2026 Earnings Call Transcript - Feb 9th, 2026 7:48 am
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot - Feb 9th, 2026 5:35 am
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update - Feb 9th, 2026 5:30 am
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 - Feb 3rd, 2026 5:30 am
Anavex Life Sciences Highlights Oral Alzheimer’s Drug Blarcamesine, Precision Strategy at JPM Conference - Jan 15th, 2026 2:06 am
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease - Jan 13th, 2026 5:30 am
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology - Jan 8th, 2026 5:30 am
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program - Jan 6th, 2026 5:30 am
Analyzing 3 Promising Penny Stocks With Market Caps Over $60M - Dec 31st, 2025 11:05 am
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion - Dec 18th, 2025 5:30 am